Should a Struggling Medtech Company Get a Second Chance: Interview With IONIQ CEO Jared Bauer
October 28, 2021
IONIQ CEO, Jared Bauer – a self-described “heavy thinker” was featured in a recent episode of Medsider.
Bauer explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet.
IONIQ Sciences, using bioimpedance, is developing a device that can potentially detect cancers in early stages. The company’s device was granted a breakthrough designation for lung cancer by the FDA in 2020.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
